We want to ensure optimum use of our website for you, and to continually improve our website. Therefore, we work with selected partners (e.g. Pardot). You can revoke your voluntary consent at any time. You can find further information and setting options under „Configure“ and in our data protection information.
Elekta will publish its May-April 2013/14 Year-end report on May 28, as per:
To take part in the conference call, please dial in about five minutes in advance,
use the telephone numbers below and the access code 944936.
The telephone conference will be broadcasted live online (for the possibility to ask questions, please also dial in). Please use the link:
# # #
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.
Johan Andersson, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451,
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017,